Omeprazole Liconsa

Omeprazole, the active ingredient in Omeprazole Liconsa, is a proton pump inhibitor presented as a oral dosage form for oral use. It reduces gastric acid production and is used to manage conditions such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults and children. GNH USA supplies Omeprazole Liconsa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Omeprazole Liconsa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole Liconsa is a proton‑pump inhibitor that acts on the gastric acid secretion pathway to treat several acid‑related disorders.

- Gastro‑oesophageal reflux disease (GERD): Improves heartburn and esophageal irritation by reducing stomach acid. - Peptic ulcer disease: Promotes healing of gastric and duodenal ulcers through acid suppression. - NSAID‑induced gastric ulcer: Protects the stomach lining by lowering acid exposure. - Helicobacter pylori eradication (in combination therapy): Enhances the effectiveness of antibiotic regimens by creating a less acidic environment. - Zollinger‑Ellison syndrome: Controls excessive gastric acid production associated with gastrin‑producing tumors.

Omeprazole may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: Mild to moderate headache reported in some patients. - Diarrhea: Loose stools occurring during short‑term therapy. - Nausea: Transient feeling of queasiness. - Abdominal pain: Mild discomfort in the stomach area. - Flatulence: Increased intestinal gas. - Constipation: Reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: Severe colitis associated with antibiotic‑like disruption of gut flora. - Hypomagnesemia: Low magnesium levels that may cause muscle cramps or cardiac arrhythmia. - Acute interstitial nephritis: Inflammation of the kidney interstitium. - Stevens‑Johnson syndrome: Rare severe skin reaction. - Fracture risk: Potential increase in hip, wrist or spine fractures with long‑term use.

When prescribing Omeprazole Liconsa, clinicians should consider several safety aspects.

- Assess renal function: Adjust use in patients with severe renal impairment. - Evaluate hepatic status: Use with caution in moderate to severe liver disease. - Monitor long‑term therapy: Review need for continued treatment after 8‑12 weeks. - Consider drug‑induced nutrient deficiencies: Monitor magnesium and vitamin B12 levels during prolonged use. - Avoid in known hypersensitivity: Discontinue if allergic reaction occurs. - Store at below 25°C: Keep in the original packaging, protect from moisture and light.

Omeprazole Liconsa can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Ketoconazole: Reduced absorption of the antifungal due to increased gastric pH. - Atazanavir: Decreased plasma concentrations compromising antiviral efficacy. - Clopidogrel: Potential reduction in antiplatelet activity.

Moderate Interactions (Monitor Closely): - Warfarin: May enhance anticoagulant effect, requiring INR monitoring. - Digoxin: Possible increase in serum levels. - Methotrexate: May raise systemic exposure, especially at high doses.